Toutes les études
RecrutementPHASE2, PHASE3INTERVENTIONNEL

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

This research is looking into a new treatment called KYV-101 for adults living with generalized myasthenia gravis, a condition that causes muscle weakness. Myasthenia gravis is an autoimmune disease, meaning the body's immune system mistakenly attacks healthy tissues, in this case, parts of the muscles. The new treatment, KYV-101, is a type of cell therapy that works by targeting and removing specific immune cells called B cells, which are thought to play a role in causing myasthenia gravis. The study aims to find out if KYV-101 is safe and effective in reducing the symptoms of muscle weakness and improving the overall quality of life for those with the condition. It’s a significant step towards finding new ways to manage this challenging disease.

En un coup d'œil

Statut
Recrutement
Phase
PHASE2, PHASE3
Sponsor
Kyverna Therapeutics
Objectif d'inscription
66
Démarrer
28 août 2024
Achèvement estimé
01 Sep 2028

De quoi parle cette étude ?

Myasthenia gravis is a long-term condition where your muscles become weak and tired easily because your immune system mistakenly attacks the connections between your nerves and muscles. This can make everyday tasks like walking, talking, or even smiling difficult. While there are treatments available, they don't work for everyone, and some people still experience significant challenges.

This study is exploring a new type of treatment called KYV-101, which is a cell therapy. Think of it as retraining your body's own defense system. The treatment specifically targets and removes certain immune cells, called B cells, which are believed to be heavily involved in causing myasthenia gravis. By getting rid of these problematic B cells, the hope is to reduce the immune system's attack on your muscles and lessen your symptoms.

The researchers want to see if KYV-101 can safely and effectively improve muscle strength and overall well-being for people living with generalized myasthenia gravis. This research is important because it could offer a new option for patients who haven't found enough relief from current treatments. It’s about finding better ways to help people regain more control over their daily lives.

Points clés

  • This study is testing a new cell therapy (KYV-101) for generalized myasthenia gravis.
  • The therapy aims to reduce muscle weakness by targeting specific immune cells.
  • It's for adults aged 18-75 who haven't fully responded to other treatments.
  • Participation involves ongoing monitoring and clinic visits.
  • The study could provide a new treatment option for myasthenia gravis.
  • Vous pouvez vous retirer de l'étude à tout moment.

Qui peut être éligible ?

This study is looking for adults aged 18 to 75 who have been diagnosed with generalized myasthenia gravis. To be considered, you would need to have specific antibodies in your blood related to myasthenia gravis, and your muscle weakness should be at a certain level according to standard medical tests.

You would also need to have tried and not fully responded to at least two other common treatments for myasthenia gravis, or one treatment if you regularly need procedures like plasma exchange or IVIG to manage your symptoms. Your current medications for myasthenia gravis should also be at a stable dose for a certain period before joining.

There are also some reasons why you might not be able to join. For example, if you have other serious neurological conditions, an uncontrolled mental health illness, or certain other medical problems that the doctors think would make participating unsafe or complicate the study's results, you might not be eligible.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous entre 18 et 75 ans ?
  2. Have you been diagnosed with generalized myasthenia gravis?
  3. Have you tried at least two other common myasthenia gravis treatments that weren't fully effective?
  4. Êtes-vous en mesure d'assister à des visites régulières à la clinique ?
  5. Do you have the specific antibodies related to myasthenia gravis in your blood?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part, you would have several visits to the study clinic for check-ups and assessments. The main treatment involves a special process where some of your immune cells (T-cells) are collected, sent away to be modified to become KYV-101, and then given back to you as an infusion. Before this, you might receive some short-term treatment to prepare your body.

Throughout the study, you'd have regular blood tests, physical examinations, and assessments of your muscle strength and daily activities to see how the treatment is affecting you. The total duration of your participation would involve the treatment period and then regular follow-up visits to monitor your health and the treatment’s effects. You’ll be told the exact schedule of visits and procedures if you are interested in joining.

Risques et avantages potentiels

Participating in any clinical trial has potential benefits and risks. You might benefit from a new treatment that could improve your myasthenia gravis symptoms, and you'd be contributing to medical research that could help others in the future. However, there are potential risks, as KYV-101 is an experimental treatment, and its side effects are still being fully understood. These could include reactions from the cell infusion or effects on your immune system. Doctors will carefully monitor you for any problems. Remember, you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (22)

  • Ronald Reagan UCLA Medical Center
    Code postal vérifié
    Los Angeles, États-Unis· Recrutement
  • University of California, Irvine
    Code postal vérifié
    Orange, United States· Recrutement
  • Stanford University Medical Center
    Code postal vérifié
    Palo Alto, United States· Recrutement
  • University of Miami
    Code postal vérifié
    Miami, États-Unis· Recrutement
  • Indiana University Health
    Code postal vérifié
    Indianapolis, États-Unis· Recrutement
  • University of Missouri
    Code postal vérifié
    Columbia, United States· Recrutement
  • Oregon Health & Science University
    Code postal vérifié
    Portland, États-Unis· Recrutement
  • Thomas Jefferson University Hospital
    Code postal vérifié
    Philadelphie, États-Unis· Recrutement
  • Houston Methodist Hospital
    Code postal vérifié
    Houston, États-Unis· Recrutement
  • Intermountain Medical Center
    Code postal vérifié
    Murray, United States· Recrutement
  • Westmead Institute for Medical Research
    Code postal vérifié
    Westmead, Australia· Recrutement
  • Hospital Israelita Albert Einstein
    Code postal vérifié
    São Paulo, Brésil· Recrutement

Questions fréquentes

What is generalized myasthenia gravis?

It's a long-term condition that causes muscle weakness and tiredness due to your immune system attacking the connections between nerves and muscles.

What is KYV-101?

It's a new type of cell therapy that works by targeting and removing specific immune cells called B cells, which are involved in myasthenia gravis.

How is KYV-101 given?

Your own immune cells are collected, modified, and then given back to you as an infusion (like a drip).

Will I still take my regular myasthenia gravis medication?

You'll need to be on stable doses of your current medications for a period before the study, and your doctors will advise on any changes during the trial.

What are the phases of this study?

This study is in Phase 2 and Phase 3, meaning it's still testing the safety and effectiveness of the new treatment in larger groups of people.

Comment en savoir plus

Kyverna Therapeutics, Inc.

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cel… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.